LAFAYETTE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it will host its Quarterly Conference Call on Thursday, August 8, 2024 at 11:00 a.m. ET.
Interested parties may participate in the call by dialing:
888-437-3179 (US Toll-Free)
+1 862-298-0702 (International)
Financial professionals are invited to call in to register in advance to ask questions. To pre-register as a qualified caller, please e-mail This email address is being protected from spambots. You need JavaScript enabled to view it. by 12:00 p.m. ET Wednesday, August 7, 2024.
Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=V8qNtmZw
Following the live call, a replay will be available in the Investor Relations section of the Company’s website, www.viemed.com.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. Visit our website at www.viemed.com.
For further information, please contact:
Glen Akselrod
Bristol Capital
905-326-1888
This email address is being protected from spambots. You need JavaScript enabled to view it.
Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$8.61 |
Daily Change: | -0.27 -3.04 |
Daily Volume: | 64,302 |
Market Cap: | US$334.330M |
April 02, 2024 March 06, 2024 November 07, 2023 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB